173 related articles for article (PubMed ID: 19220493)
1. Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution.
Williams P; Wu J; Cohn S; Koletar S; McCutchan J; Murphy R; Currier J;
HIV Med; 2009 May; 10(5):290-301. PubMed ID: 19220493
[TBL] [Abstract][Full Text] [Related]
2. Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Dai L; Liu A; Zhang H; Wu H; Zhang T; Su B; Shao Y; Li J; Ye J; Scott SR; Mahajan SD; Schwartz SA; Yu H; Sun L
Curr HIV Res; 2019; 17(5):324-334. PubMed ID: 31654514
[TBL] [Abstract][Full Text] [Related]
3. Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.
Buchacz K; Weidle PJ; Moore D; Were W; Mermin J; Downing R; Kigozi A; Borkowf CB; Ndazima V; Brooks JT
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):304-11. PubMed ID: 18398971
[TBL] [Abstract][Full Text] [Related]
4. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
[TBL] [Abstract][Full Text] [Related]
5. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
[TBL] [Abstract][Full Text] [Related]
6. Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.
Bednasz C; Luque AE; Zingman BS; Fischl MA; Gripshover BM; Venuto CS; Gu J; Feng Z; DiFrancesco R; Morse GD; Ma Q
Curr Vasc Pharmacol; 2016; 14(3):280-7. PubMed ID: 26733388
[TBL] [Abstract][Full Text] [Related]
7. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs.
Stacy TA; Egger A
J Manag Care Pharm; 2006; 12(9):745-51. PubMed ID: 17249907
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal analysis of immune reconstitution and metabolic changes in women living with HIV: A real-world observational study.
Wang X; Xiao J; Zhang L; Liu Y; Chen N; Deng M; Song C; Liu T; Zhang Y; Zhao H
Chin Med J (Engl); 2023 Sep; 136(18):2168-2177. PubMed ID: 37580056
[TBL] [Abstract][Full Text] [Related]
9. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Quercia R; Roberts J; Martin-Carpenter L; Zala C
Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
[TBL] [Abstract][Full Text] [Related]
10. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
11. Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.
Gillard BK; Raya JL; Ruiz-Esponda R; Iyer D; Coraza I; Balasubramanyam A; Pownall HJ
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1714-21. PubMed ID: 23640486
[TBL] [Abstract][Full Text] [Related]
12. The effects of ART on the dynamics of lipid profiles in Chinese Han HIV-infected patients: comparison between NRTI/NNRTI and NRTI/INSTI.
Liu S; Wei B; Liang W; Chen T; Deng L; Zhao M; Wan J
Front Public Health; 2023; 11():1161503. PubMed ID: 37181701
[TBL] [Abstract][Full Text] [Related]
13. Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Madden E; Lee G; Kotler DP; Wanke C; Lewis CE; Tracy R; Heymsfield S; Shlipak MG; Bacchetti P; Scherzer R; Grunfeld C
AIDS; 2008 Mar; 22(6):707-15. PubMed ID: 18356600
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
15. Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Ofotokun I; Smithson SE; Lu C; Easley KA; Lennox JL
Am J Med Sci; 2007 Nov; 334(5):334-41. PubMed ID: 18004087
[TBL] [Abstract][Full Text] [Related]
16. Decreased Serum Lipid Levels and Ratios Correlate with Low Prevalence of Coronary Heart Disease in Patients with Parkinson's Disease.
Bao M; Hu R; Chen Y; Wang N; Xue H; He J; Jin J; Kong W; Ke G; Xue Q
Clin Lab; 2018 Sep; 64(9):1413-1419. PubMed ID: 30274018
[TBL] [Abstract][Full Text] [Related]
17. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
18. Influence of common genetic variation on blood lipid levels, cardiovascular risk, and coronary events in two British prospective cohort studies.
Shah S; Casas JP; Gaunt TR; Cooper J; Drenos F; Zabaneh D; Swerdlow DI; Shah T; Sofat R; Palmen J; Kumari M; Kivimaki M; Ebrahim S; Smith GD; Lawlor DA; Talmud PJ; Whittaker J; Day IN; Hingorani AD; Humphries SE
Eur Heart J; 2013 Apr; 34(13):972-81. PubMed ID: 22977227
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia.
Al Sifri S; Al Shammeri O; Al Jaser S; Alkhenizan A; Bin Shafi Shafiurrehman A; Morcos B; Wajih S; Elnahal I; Horack M; Brudi P; Lautsch D; Ambegaonkar B; Vyas A; Baxter CA; Gitt AK
Saudi Med J; 2018 Jul; 39(7):697-704. PubMed ID: 29968891
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
